Answers are grounded in this paper and cite their sources.
Introduction: Vincristine is used in many therapeutic schemes of oncological treatment in children and one of its common complications is neurotoxicity. The aim of the study was to assess the incidence of vincristine-induced polyneuropathy in children treated for acute lymphoblastic leukemia. Secondly, I evaluated the clinical spectrum of chemotherapy-induced peripheral neuropathy. Material and methods: The study included 29 patients with newly diagnosed acute lymphoblastic leukemia who were treated according to the ALL IC-BFM 2009 therapeutic program. The study was designed for induction remission phase, in which patients received unified anticancer treatment. The neurological assessment was performed on 1, 8, 15, 22, 29 and 36 day of treatment and consisted of an original questionnaire from patients or their caregivers, a physical examination and a neurological examination of the patients. Abnormalities were assessed according to the Common Terminology Criteria for Adverse Events version 5.0 scale. Results: Symptoms of polyneuropathy occurred in 25 patients (86.2%). Motor neuropathy was the most common type of polyneuropathy in the examined group. In half the cases, the polyneuropathy was severe, rated at 3 or 4 points. The most serious course manifested itself in severe gastrointestinal ileus with subsequent intestinal perforation in three patients. In another case, rated at 4 points, breathing disorders occurred with apnea episodes. Conclusions: Vincristine-induced polyneuropathy is common in children with acute lymphoblastic leukemia in induction of remission and is severe in half of the cases. In the pediatric population, in contrast to adults, vincristine-induced polyneuropathy motor symptoms are predominant. .
No takes yet. Share an insight, caveat, or question.
Cienkusz et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: